May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Nitroglycerin-Mediated Retinal Vasodilatation Is Maintained in Patients With Diabetes
Author Affiliations & Notes
  • G. Weigert
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
    Department of Ophthalmology,
  • B. Pemp
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
  • G. Garhofer
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
  • K. Karl
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
  • U. Petzl
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
  • M. Wolzt
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
  • L. Schmetterer
    Medical University of Vienna, Vienna, Austria
    Department of Clinical Pharmacology,
    Center for Biomedical Engineering and Physics,
  • Footnotes
    Commercial Relationships  G. Weigert, None; B. Pemp, None; G. Garhofer, None; K. Karl, None; U. Petzl, None; M. Wolzt, None; L. Schmetterer, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2088. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Weigert, B. Pemp, G. Garhofer, K. Karl, U. Petzl, M. Wolzt, L. Schmetterer; Nitroglycerin-Mediated Retinal Vasodilatation Is Maintained in Patients With Diabetes. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2088. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : A variety of studies indicate that patients with diabetes show abnormal retinal autoregulation. The mechanism behind this reduced capacity of retinal vessels to adapt to changes in perfusion pressure remains, however, largely unclear. One possibility is that diabetic retinal blood vessels show a generally reduced vasodilator and/or vasoconstrictor capacity due to the morphological changes associated with the disease. To test this hypothesis we compared the response of retinal arteries to systemic nitroglycerine in patients with diabetes and healthy controls.

Methods: : In the present study 20 patients with insulin dependent diabetes, no or mild non-proliferative diabetic retinopathy, and serum cholesterol levels < 250 mg/dl were included. In addition, 20 healthy age-matched controls were studied. Retinal vessel diameters and systemic blood pressures were studied before and immediately after a single sublingual dose of 0.8 mg of nitroglycerin. Retinal vessel diameters were measured continuously using the Imedos Retinal Vessel Analyzer. The retinal vessel response between the two groups was compared by using an unpaired t-test.

Results: : The vasodilatory response of retinal arterial diameter to nitroglycerin was 1.64% ± 0.78% in patients with diabetes and 1.67% ± 0.78% in healthy control subjects. Likewise, the retinal venous vasodilatory response was 1.57% ± 0.71% in patients with diabetes and 1.67% ± 0.66% in healthy control subjects. Neither the nitroglycerine-induced vasodilatation in retinal arteries nor in retinal veins was different between the two groups. Systemic blood pressure was reduced in both groups after systemic nitroglycerin, but to a comparable degree.

Conclusions: : The present study indicates that in patents with diabetes with no or mild non-proliferative diabetic retinopathy the retinal vessel response to a direct nitro-vasodilator is maintained. This indicates that abnormal retinal autoregulation, as observed previously, is not the consequence of a generally reduced retinal vascular reactivity of retinal vessels in this disease.

Clinical Trial: : www.clinicaltrials.gov NCT00432029

Keywords: retina • nitric oxide • diabetes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×